首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NRG4 |
| Uniprot No | Q8WWG1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-61aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMPTDHEE PCGPSHKSFC LNGGLCYVIP TIPSPFCRCV ENYTGARCEE VFLPGSSIQT KSNL |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NRG4重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **"Recombinant NRG4 Ameliorates Metabolic Dysfunction in Diet-Induced Obesity Models"**
*Authors: Chen L, Wang Y, et al.*
**摘要**：研究通过表达纯化重组人NRG4蛋白，验证其在肥胖小鼠模型中改善胰岛素抵抗和脂肪肝的作用，证实其通过激活ErbB4受体调节脂质代谢通路。
2. **"Functional Characterization of NRG4 Isoforms in Cancer Cell Proliferation"**
*Authors: Kim S, Patel R, et al.*
**摘要**：探讨不同重组NRG4异构体对乳腺癌细胞增殖的影响，发现β3亚型通过MAPK信号通路显著抑制肿瘤生长，提示其潜在治疗价值。
3. **"Optimization of Recombinant NRG4 Production in E. coli for Clinical Applications"**
*Authors: Müller F, Jensen K, et al.*
**摘要**：开发高效大肠杆菌表达系统生产功能性NRG4重组蛋白，优化折叠条件及纯化工艺，证明其体外促进神经元突触再生的生物活性。
4. **"NRG4 Attenuates Cardiac Fibrosis via Paracrine Signaling in a Rat Model"**
*Authors: Gupta A, Sharma P, et al.*
**摘要**：利用重组NRG4蛋白干预心肌纤维化大鼠模型，发现其通过抑制TGF-β1通路减少胶原沉积，为心血管疾病治疗提供新靶点。
---
**注**：以上文献为模拟内容，实际引用需查询权威数据库(如PubMed、Web of Science)获取真实研究。
**Background of NRG4 Recombinant Protein**
Neuregulin 4 (NRG4), a member of the neuregulin family of growth factors, plays a critical role in cellular signaling and tissue homeostasis. Structurally, it contains an epidermal growth factor (EGF)-like domain that enables interaction with ErbB receptor tyrosine kinases, primarily ErbB3 and ErbB4. This interaction activates downstream pathways, such as PI3K/AKT and MAPK, regulating processes like cell proliferation, differentiation, and survival. NRG4 is predominantly expressed in secretory epithelial cells, adipose tissue, and the digestive tract, functioning as a hormone-like factor.
Emerging research highlights NRG4's metabolic significance. It is secreted by adipose tissue, particularly brown and beige fat, and acts as an endocrine regulator. Studies link NRG4 to improved insulin sensitivity, lipid metabolism, and energy homeostasis. Animal models demonstrate that NRG4 deficiency exacerbates obesity-related metabolic disorders, such as hepatic steatosis and insulin resistance, while its overexpression or exogenous administration ameliorates these conditions. These findings position NRG4 as a potential therapeutic target for metabolic diseases, including type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).
Recombinant NRG4 protein, produced via genetic engineering in systems like *E. coli* or mammalian cells, retains the bioactive properties of endogenous NRG4. Its development enables mechanistic studies and preclinical testing. Current efforts focus on optimizing delivery methods (e.g., fusion proteins, sustained-release formulations) and evaluating safety and efficacy in metabolic disorder models. Challenges include understanding tissue-specific signaling and minimizing off-target effects. Nonetheless, recombinant NRG4 holds promise as a novel biologic therapy, bridging gaps in managing complex metabolic syndromes.
×
